Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 13/20 | 0.36 |
| ▸ | CASP3 | P42574 | 5/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067192 | 0.90 | ADORA3 (0.39) | CASP1CASP3MMEADORA3ADORA2A | |
| SCHEMBL4058454 | 0.78 | MMP9 (0.42) | CASP1CASP3MMEADORA3ADORA2A | |
| SCHEMBL4064462 | 0.70 | ADORA3 (0.40) | MMEADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4056317 | 0.69 | PSEN1 (0.44) | MMEADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4062416 | 0.67 | PSEN1 (0.46) | MMEADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4056892 | 0.66 | PSEN1 (0.41) | MMEADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4055360 | 0.63 | MAPK8 (0.39) | MMEADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL8313476 | 0.60 | PSEN1 (0.42) | — | |
| SCHEMBL8320833 | 0.60 | PSEN1 (0.42) | — | |
| SCHEMBL4058155 | 0.60 | ADORA3 (0.45) | MMEADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| US-7521464-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | CASP1 389/4885CASP3 759/4885MME 1913/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | CASP1 2795/4885CASP3 3350/4885MME 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.